Press Releases

Press Releases
Publications
Presentations
Events

Latest Press Releases

12/07/2020
Triphase Accelerator Announces Positive Interim Results of Phase 1 Trial of TRPH-222 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
5/18/2020
Triphase Accelerator and Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222 in Patients with Non-Hodgkin’s Lymphoma
04/01/2019
Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
1/29/2019
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
12/4/2017
Triphase Accelerator to Present Investigational New Drug Enabling Data for TRPH-222
5/1/2017
Triphase Accelerator Reports Completion of Initial Regulatory Interactions with FDA and Health Canada for TRPH-222 for the Treatment of Lymphoma
12/21/16
Triphase Accelerator Announces New Collaboration with Celgene Corporation for TRPH-222, an anti-CD22 Antibody Drug Conjugate
11/18/16
Triphase Accelerator Corporation Announces Full Enrollment Results of Its Phase 1 Trial of Marizomib and Bevacizumab in Malignant …
11/17/16
Triphase Accelerator Announces Acquisition of its First Compound, Marizomib, by Celgene Corporation
10/04/16
Catalent Biologics And Triphase Accelerator Corportion Announce License Agreement To Advance SMARTagTM ADC To Clinic
06/04/16
Triphase Accelerator Corporation Announces Positive Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma
05/03/16
Triphase Accelerator Corporation Announces Expansion of Collaboration with Celgene in the Development of Marizomib for the Treatment of Gliomas
04/19/16
Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma
04/18/16
Triphase Accelerator Corporation Announces Positive Preclinical Results for CBZed-Nano™ in Docetaxel-Resistant Prostate Cancer Models

View Press Release Archive